ArticleJournal of nanobiotechnology2026
M2 Macrophage membrane-mediated biomimetic nanoparticles carrying ADAM9 siRNA alleviate renal inflammation and fibrosis via the AKT/NF-κB pathway.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The chronic kidney disease (CKD) situation remains severe globally. The prevention and management of CKD continue to be long-term and challenging tasks. A disintegrin and metalloprotease 9 (ADAM9) is a key factor in the progression of fibrosis and acts through multiple mechanisms, making it an important target in the study of fibrotic diseases. Thus, therapeutic strategies targeting ADAM9 hold promise for treating fibrotic disorders. This study aimed to utilize nanoparticle complexes coated with macrophage membranes (designated M2M@NP complexes) to deliver small interfering RNAs (siRNAs) targeting ADAM9 expression in the kidney. This approach was intended to exert a therapeutic effect on the progression of kidney disease. In vivo imaging confirmed that the macrophage membrane carrier exhibited excellent inflammation-targeting properties. In vitro and in vivo characterization confirmed that M2M@NPs possessed superior transfection efficiency and safety. The experimental results indicated that M2M@NP-ADAM9 siRNA complexes effectively reduced ADAM9 expression, thereby inhibiting the protein kinase B (AKT)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and reducing Ras-related C3 botulinum toxin substrate 1 (RAC1) and tumor necrosis factor receptor-associated factor 6 (TRAF6) expression. These complexes also reduced macrophage infiltration and M1 polarization, leading to attenuated renal inflammation and fibrosis. Our findings suggest that the M2M@NP delivery system has broad potential for treating CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.